Home LiteratureArticle Details
PMID: 23303139 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Nature reviews. Cancer ·Vol. 13 ·No. 2 ·2013-02-00 ·Pages 83-96

Wade M, Li YC, Wahl GM

Abstract

The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour suppressor. However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded. Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for determining responses to oncogenic and therapeutic challenges. This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.

MeSH Terms
Animals Cell Transformation, Neoplastic/genetics,metabolism Humans Neoplasms/genetics,metabolism,therapy Proto-Oncogene Proteins c-mdm2/genetics,metabolism Tumor Suppressor Protein p53/genetics,metabolism
Chemicals
Tumor Suppressor Protein p53 Proto-Oncogene Proteins c-mdm2
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Wade Mark
Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Via Adamello 16, 20139 Milan, Italy.
Li Yao-Cheng
Wahl Geoffrey M
References (174)
174 references, click to expand
  1. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.
    Cancer Res. 2005 Sep 1;65(17):7644-52 PMID: 16140930
  2. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.
    Genes Dev. 2001 May 1;15(9):1067-77 PMID: 11331603
  3. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Cell Death Dis. 2011 May 12;2:e156 PMID: 21562588
  4. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.
    EMBO J. 2007 Jan 10;26(1):90-101 PMID: 17170710
  5. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.
    Nature. 2006 Sep 14;443(7108):214-7 PMID: 16957739
  6. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.
    Cancer Res. 2011 Jun 15;71(12):4205-13 PMID: 21515735
  7. Small molecules that bind the Mdm2 RING stabilize and activate p53.
    Carcinogenesis. 2012 Apr;33(4):791-8 PMID: 22301280
  8. HSP90 and the chaperoning of cancer.
    Nat Rev Cancer. 2005 Oct;5(10):761-72 PMID: 16175177
  9. A restricted cell population propagates glioblastoma growth after chemotherapy.
    Nature. 2012 Aug 23;488(7412):522-6 PMID: 22854781
  10. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.
    Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11995-2000 PMID: 21730132
  11. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
    Cancer Cell. 2010 Sep 14;18(3):220-30 PMID: 20832750
  12. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.
    Cancer Res. 2010 Sep 15;70(18):7148-54 PMID: 20736370
  13. Coordinate regulation of estrogen receptor β degradation by Mdm2 and CREB-binding protein in response to growth signals.
    Oncogene. 2013 Jan 3;32(1):117-26 PMID: 22349818
  14. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities.
    Differentiation. 2009 Jun;77(5):442-9 PMID: 19371999
  15. Will the ubiquitin system furnish as many drug targets as protein kinases?
    Cell. 2010 Nov 24;143(5):686-93 PMID: 21111230
  16. MdmX inhibits Smad transactivation.
    Oncogene. 2002 Dec 12;21(57):8776-85 PMID: 12483531
  17. Three-dimensional reconstruction of protein networks provides insight into human genetic disease.
    Nat Biotechnol. 2012 Jan 15;30(2):159-64 PMID: 22252508
  18. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage.
    Mol Cell Biol. 2006 Sep;26(18):6819-31 PMID: 16943424
  19. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Nature. 2012 Mar 28;483(7391):603-7 PMID: 22460905
  20. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
    Nature. 2007 Dec 13;450(7172):1001-9 PMID: 18075579
  21. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
    Lancet Oncol. 2012 Nov;13(11):1133-40 PMID: 23084521
  22. Awakening guardian angels: drugging the p53 pathway.
    Nat Rev Cancer. 2009 Dec;9(12):862-73 PMID: 19935675
  23. Protein kinase CK1delta phosphorylates key sites in the acidic domain of murine double-minute clone 2 protein (MDM2) that regulate p53 turnover.
    Biochemistry. 2004 Dec 28;43(51):16356-64 PMID: 15610030
  24. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.
    J Biol Chem. 2002 Feb 15;277(7):5484-9 PMID: 11729185
  25. Restoration of p53 function leads to tumour regression in vivo.
    Nature. 2007 Feb 8;445(7128):661-5 PMID: 17251932
  26. MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.
    EMBO J. 2010 Aug 4;29(15):2538-52 PMID: 20588255
  27. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
    Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3232-7 PMID: 16492744
  28. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding.
    J Biol Chem. 2008 May 16;283(20):13707-13 PMID: 18356162
  29. The emerging functions of the p53-miRNA network in stem cell biology.
    Cell Cycle. 2012 Jun 1;11(11):2063-72 PMID: 22580472
  30. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.
    PLoS One. 2012;7(8):e42034 PMID: 22870278
  31. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.
    Oncogene. 2008 Mar 6;27(11):1590-8 PMID: 17828300
  32. Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action.
    Mol Syst Biol. 2010 Dec 21;6:451 PMID: 21179023
  33. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
    Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14321-6 PMID: 20660730
  34. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Science. 1996 Nov 8;274(5289):948-53 PMID: 8875929
  35. Mdm2 promotes genetic instability and transformation independent of p53.
    Mol Cell Biol. 2008 Aug;28(15):4862-74 PMID: 18541670
  36. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
    Mol Cell Biol. 2006 Jan;26(1):192-8 PMID: 16354690
  37. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.
    Cancer Cell. 2009 Jul 7;16(1):33-43 PMID: 19573810
  38. HdmX overexpression inhibits oncogene induced cellular senescence.
    Cell Cycle. 2010 Aug 15;9(16):3376-82 PMID: 20724842
  39. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Cancer Res. 2007 Sep 15;67(18):8810-7 PMID: 17875722
  40. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma.
    PLoS One. 2012;7(8):e42739 PMID: 22916154
  41. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Science. 2004 Feb 6;303(5659):844-8 PMID: 14704432
  42. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
    Cancer Cell. 2005 Jun;7(6):547-59 PMID: 15950904
  43. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process.
    EMBO J. 2011 Feb 2;30(3):468-79 PMID: 21157430
  44. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
    EMBO J. 2005 Oct 5;24(19):3411-22 PMID: 16163388
  45. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
    Nat Chem Biol. 2012 Jul;8(7):646-54 PMID: 22660439
  46. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
    Nat Med. 2004 Dec;10(12):1321-8 PMID: 15558054
  47. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Nature. 1995 Nov 9;378(6553):203-6 PMID: 7477326
  48. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
    EMBO J. 2007 Jan 10;26(1):102-12 PMID: 17159902
  49. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
    Mol Cell. 2012 Mar 30;45(6):754-63 PMID: 22464442
  50. Full-length hdmX transcripts decrease following genotoxic stress.
    Oncogene. 2008 Nov 6;27(52):6657-66 PMID: 18711402
  51. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis.
    Oncogene. 1995 Jul 6;11(1):175-9 PMID: 7624125
  52. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.
    Genes Dev. 1997 Mar 15;11(6):714-25 PMID: 9087426
  53. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.
    Cancer Cell. 2007 Oct;12(4):355-66 PMID: 17936560
  54. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
    Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12009-14 PMID: 14507994
  55. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Clin Cancer Res. 2006 Aug 15;12(16):4867-71 PMID: 16914573
  56. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer.
    Clin Cancer Res. 2012 Aug 15;18(16):4325-33 PMID: 22733537
  57. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.
    Cancer Cell. 2010 Oct 19;18(4):367-81 PMID: 20951946
  58. ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice.
    Cancer Cell. 2012 May 15;21(5):668-679 PMID: 22624716
  59. p53-mediated hematopoietic stem and progenitor cell competition.
    Cell Stem Cell. 2010 Apr 2;6(4):309-22 PMID: 20362536
  60. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.
    Cell. 2000 Oct 13;103(2):321-30 PMID: 11057904
  61. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
    Cell. 1992 Jun 26;69(7):1237-45 PMID: 1535557
  62. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    J Med Chem. 2006 Jun 15;49(12):3432-5 PMID: 16759082
  63. Chromatin-modifying enzymes as modulators of reprogramming.
    Nature. 2012 Mar 04;483(7391):598-602 PMID: 22388813
  64. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
    Semin Cancer Biol. 2010 Feb;20(1):19-28 PMID: 19897041
  65. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy.
    Circulation. 2007 Jun 12;115(23):2925-30 PMID: 17533180
  66. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
    Cancer Res. 2010 Dec 1;70(23):9641-9 PMID: 21084273
  67. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity.
    Genes Dev. 2011 Jul 1;25(13):1426-38 PMID: 21724834
  68. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo.
    J Pathol. 2011 Jan;223(2):127-36 PMID: 20957626
  69. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.
    J Biol Chem. 2012 Aug 31;287(36):30468-76 PMID: 22787160
  70. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.
    Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603 PMID: 11504915
  71. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
    Genes Chromosomes Cancer. 2010 Jun;49(6):518-25 PMID: 20196171
  72. MdmX regulates transformation and chromosomal stability in p53-deficient cells.
    Cell Cycle. 2008 Oct;7(19):2967-73 PMID: 18818521
  73. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.
    Cell Cycle. 2008 Jul 1;7(13):1973-82 PMID: 18604177
  74. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation.
    J Biol Chem. 2004 Aug 20;279(34):35510-7 PMID: 15169778
  75. Deconstructing p53 transcriptional networks in tumor suppression.
    Trends Cell Biol. 2012 Feb;22(2):97-106 PMID: 22154076
  76. Inactivation of the p53 pathway in retinoblastoma.
    Nature. 2006 Nov 2;444(7115):61-6 PMID: 17080083
  77. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival.
    Cell Death Differ. 2008 Nov;15(11):1772-81 PMID: 18636077
  78. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice.
    J Hepatol. 2012 Oct;57(4):837-43 PMID: 22641095
  79. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.
    EMBO J. 2009 Dec 16;28(24):3857-67 PMID: 19816404
  80. The microcosmos of cancer.
    Nature. 2012 Feb 15;482(7385):347-55 PMID: 22337054
  81. RNA therapeutics: beyond RNA interference and antisense oligonucleotides.
    Nat Rev Drug Discov. 2012 Jan 20;11(2):125-40 PMID: 22262036
  82. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2.
    Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18061-6 PMID: 20921405
  83. Met acts on Mdm2 via mTOR to signal cell survival during development.
    Development. 2007 Apr;134(7):1443-51 PMID: 17329361
  84. Building ubiquitin chains: E2 enzymes at work.
    Nat Rev Mol Cell Biol. 2009 Nov;10(11):755-64 PMID: 19851334
  85. Nutlin-3a is a potential therapeutic for ewing sarcoma.
    Clin Cancer Res. 2011 Feb 1;17(3):494-504 PMID: 21098696
  86. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism.
    Biochem Pharmacol. 1999 Jun 1;57(11):1283-95 PMID: 10230772
  87. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response.
    Cancer Res. 2009 Oct 15;69(20):7960-8 PMID: 19808970
  88. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
    Clin Cancer Res. 2011 Feb 1;17(3):416-26 PMID: 21159888
  89. Combinatorial drug therapy for cancer in the post-genomic era.
    Nat Biotechnol. 2012 Jul 10;30(7):679-92 PMID: 22781697
  90. MdmX represses E2F1 transactivation.
    Cell Cycle. 2004 Apr;3(4):472-8 PMID: 14739777
  91. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers.
    Mol Cancer Res. 2008 Feb;6(2):205-11 PMID: 18314481
  92. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.
    J Virol. 2012 Jun;86(12):6889-98 PMID: 22496226
  93. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.
    Hepatology. 2011 Aug;54(2):522-31 PMID: 21563203
  94. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
    EMBO J. 2003 Mar 17;22(6):1442-50 PMID: 12628936
  95. Regulation of MDMX expression by mitogenic signaling.
    Mol Cell Biol. 2008 Mar;28(6):1999-2010 PMID: 18172009
  96. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Cancer Lett. 2005 Oct 18;228(1-2):21-7 PMID: 15927364
  97. RING domain E3 ubiquitin ligases.
    Annu Rev Biochem. 2009;78:399-434 PMID: 19489725
  98. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
    Mol Cancer Ther. 2012 Jun;11(6):1247-56 PMID: 22461661
  99. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability.
    Cell. 2001 Nov 2;107(3):323-37 PMID: 11701123
  100. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation.
    Cell Death Differ. 2012 Aug;19(8):1381-9 PMID: 22388350
  101. Distinct roles of Mdm2 and Mdm4 in red cell production.
    Blood. 2007 Mar 15;109(6):2630-3 PMID: 17105817
  102. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.
    Cancer Res. 2010 Mar 15;70(6):2424-34 PMID: 20215498
  103. Hdmx modulates the outcome of p53 activation in human tumor cells.
    J Biol Chem. 2006 Nov 3;281(44):33036-44 PMID: 16905769
  104. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.
    Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61 PMID: 15788536
  105. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
    Mol Cell Biol. 2007 Aug;27(15):5479-85 PMID: 17526734
  106. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase.
    EMBO J. 2002 Aug 1;21(15):4037-48 PMID: 12145204
  107. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
    Cancer Res. 2006 Mar 15;66(6):3169-76 PMID: 16540668
  108. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
    Nat Genet. 2001 Sep;29(1):92-5 PMID: 11528400
  109. Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.
    Mol Cell Biol. 2010 Nov;30(22):5394-405 PMID: 20855528
  110. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability.
    Cell Cycle. 2008 Jan 15;7(2):164-8 PMID: 18333294
  111. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction.
    Cancer Cell. 2010 Sep 14;18(3):231-43 PMID: 20832751
  112. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.
    Mol Cancer Ther. 2011 Jan;10(1):69-79 PMID: 21075910
  113. p53-mediated heterochromatin reorganization regulates its cell fate decisions.
    Nat Struct Mol Biol. 2012 Apr 01;19(5):478-84, S1 PMID: 22466965
  114. Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells.
    J Biol Chem. 2006 Jun 16;281(24):16814-20 PMID: 16621805
  115. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
    Clin Cancer Res. 2009 Feb 1;15(3):933-42 PMID: 19188164
  116. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
    Mol Cancer Res. 2009 Jan;7(1):1-11 PMID: 19147532
  117. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    J Biol Chem. 2006 Nov 3;281(44):33030-5 PMID: 16905541
  118. A crucial role for adipose tissue p53 in the regulation of insulin resistance.
    Nat Med. 2009 Sep;15(9):1082-7 PMID: 19718037
  119. The p53 orchestra: Mdm2 and Mdmx set the tone.
    Trends Cell Biol. 2010 May;20(5):299-309 PMID: 20172729
  120. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
    J Clin Invest. 2007 Apr;117(4):1019-28 PMID: 17364023
  121. Murine double minute 2: p53-independent roads lead to genome instability or death.
    Trends Biochem Sci. 2009 Jun;34(6):279-86 PMID: 19447627
  122. Stapled peptides for intracellular drug targets.
    Methods Enzymol. 2012;503:3-33 PMID: 22230563
  123. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
    Cell Cycle. 2010 Mar 15;9(6):1104-11 PMID: 20237429
  124. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.
    Curr Opin Oncol. 2011 Jul;23(4):373-8 PMID: 21552124
  125. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4665-70 PMID: 19255450
  126. Mdm2-mediated ubiquitylation: p53 and beyond.
    Cell Death Differ. 2010 Jan;17(1):93-102 PMID: 19498444
  127. Role of Mdm4 in drug sensitivity of breast cancer cells.
    Oncogene. 2010 Apr 22;29(16):2415-26 PMID: 20140020
  128. On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53.
    PLoS One. 2012;7(6):e37518 PMID: 22675482
  129. MDM4 is a key therapeutic target in cutaneous melanoma.
    Nat Med. 2012 Aug;18(8):1239-47 PMID: 22820643
  130. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
    Genes Dev. 2011 Aug 15;25(16):1746-57 PMID: 21852537
  131. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway.
    J Virol. 2009 Jul;83(13):6739-47 PMID: 19369353
  132. MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells.
    J Mol Endocrinol. 2011 Feb 15;46(2):67-79 PMID: 21169420
  133. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
    Nature. 2008 Oct 23;455(7216):1061-8 PMID: 18772890
  134. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
    Cancer Discov. 2011 Sep;1(4):312-25 PMID: 22586610
  135. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.
    Mol Cancer Ther. 2008 May;7(5):1101-9 PMID: 18483299
  136. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.
    J Virol. 2009 Mar;83(6):2491-9 PMID: 19144715
  137. Translating p53 into the clinic.
    Nat Rev Clin Oncol. 2011 Jan;8(1):25-37 PMID: 20975744
  138. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.
    Mol Cell Biol. 2004 Jul;24(13):5835-43 PMID: 15199139
  139. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
    Cell Cycle. 2010 Apr 1;9(7):1373-9 PMID: 20305378
  140. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.
    Genes Dev. 1994 Aug 1;8(15):1739-49 PMID: 7958853
  141. Systematic identification of genomic markers of drug sensitivity in cancer cells.
    Nature. 2012 Mar 28;483(7391):570-5 PMID: 22460902
  142. Identification and characterization of the first small molecule inhibitor of MDMX.
    J Biol Chem. 2010 Apr 2;285(14):10786-96 PMID: 20080970
  143. Regulation of p53-MDMX interaction by casein kinase 1 alpha.
    Mol Cell Biol. 2005 Aug;25(15):6509-20 PMID: 16024788
  144. Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis.
    Nature. 2012 Sep 6;489(7414):115-20 PMID: 22842904
  145. Structure-based design of novel inhibitors of the MDM2-p53 interaction.
    J Med Chem. 2012 Jun 14;55(11):4936-54 PMID: 22524527
  146. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.
    Cancer Cell. 2006 Dec;10(6):501-14 PMID: 17157790
  147. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo.
    J Biol Chem. 2004 Oct 1;279(40):42169-81 PMID: 15280377
  148. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.
    Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15608-12 PMID: 9861017
  149. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.
    Mol Cancer Ther. 2010 Sep;9(9):2545-57 PMID: 20736344
  150. c-Abl phosphorylates Hdmx and regulates its interaction with p53.
    J Biol Chem. 2009 Feb 6;284(6):4031-9 PMID: 19075013
  151. Drug-target network.
    Nat Biotechnol. 2007 Oct;25(10):1119-26 PMID: 17921997
  152. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.
    Mol Pharmacol. 1999 Sep;56(3):478-84 PMID: 10462535
  153. Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.
    Mol Cancer. 2011 Sep 12;10:111 PMID: 21910853
  154. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
    Nature. 2007 Feb 8;445(7128):656-60 PMID: 17251933
  155. Modeling the therapeutic efficacy of p53 restoration in tumors.
    Cell. 2006 Dec 29;127(7):1323-34 PMID: 17182091
  156. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.
    Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11788-93 PMID: 22745160
  157. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
    Clin Cancer Res. 1995 Jul;1(7):769-73 PMID: 9816044
  158. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases.
    J Biol Chem. 2012 Jun 29;287(27):22959-68 PMID: 22584579
  159. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
    J Biol Chem. 2010 Sep 17;285(38):29111-27 PMID: 20659896
  160. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.
    Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12001-6 PMID: 21730163
  161. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death.
    Cell Death Differ. 2006 Dec;13(12):2089-98 PMID: 16729027
  162. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
    Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3226-31 PMID: 16492743
  163. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 PMID: 16443686
  164. p53-based cancer therapy.
    Cold Spring Harb Perspect Biol. 2010 Sep;2(9):a001222 PMID: 20463003
  165. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.
    EMBO J. 1991 Jun;10(6):1565-9 PMID: 2026149
  166. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.
    J Biol Chem. 2011 Feb 11;286(6):4796-808 PMID: 21084285
  167. Intact p53-dependent responses in miR-34-deficient mice.
    PLoS Genet. 2012;8(7):e1002797 PMID: 22844244
  168. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53.
    Cancer Res. 1997 Nov 15;57(22):5013-6 PMID: 9371494
  169. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis.
    Cancer Res. 2010 Oct 1;70(19):7684-9 PMID: 20841468
  170. A survey of glioblastoma genomic amplifications and deletions.
    J Neurooncol. 2010 Jan;96(2):169-79 PMID: 19609742
  171. IFN regulatory factor 8 regulates MDM2 in germinal center B cells.
    J Immunol. 2009 Sep 1;183(5):3188-94 PMID: 19648273
  172. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
    J Biol Chem. 2000 Mar 24;275(12):8945-51 PMID: 10722742
  173. A stapled p53 helix overcomes HDMX-mediated suppression of p53.
    Cancer Cell. 2010 Nov 16;18(5):411-22 PMID: 21075307
  174. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells.
    Biochem Biophys Res Commun. 2001 Feb 16;281(1):259-65 PMID: 11178989
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3430
Published
2013-02-00
Epub
2013-00-10
Pages
83-96
Language
English
Region
England
NLM ID
101124168
PMCID
PMC4161369
Subset
IM
Grants
NCI NIH HHS · CA014195 · United States
NCI NIH HHS · R01 CA061449 · United States
NCI NIH HHS · R01‑CA61449 · United States
NIMH NIH HHS · R03‑MH089489‑01 · United States
NIMH NIH HHS · R03 MH089489 · United States
NCI NIH HHS · P30 CA014195 · United States
External Links
PubMed source DOI: 10.1038/nrc3430 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2